Carrie Ingram, APRN
Psychiatric/Mental Health · Punta Gorda, FLNPI 1316210263
Payments from drug & device makers
Across 811 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Vanda Pharmaceuticals Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Lundbeck LLC$1K
- plus $7K from 24 others
What the payments were for
- Food & beverage$14,966100%
- Education$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 111 | $1,732 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 91 | $1,260 |
| Vanda Pharmaceuticals Inc. | 45 | $1,248 |
| Otsuka America Pharmaceutical, Inc. | 65 | $1,160 |
| Alkermes, Inc. | 64 | $1,151 |
| Lundbeck LLC | 49 | $1,121 |
| Johnson & Johnson | 37 | $1,112 |
| Corium, LLC | 61 | $951 |
| Neurocrine Biosciences, Inc. | 40 | $843 |
| Teva Pharmaceuticals USA, Inc. | 41 | $815 |
| Axsome Therapeutics, Inc. | 22 | $437 |
| Ironshore Pharmaceuticals Inc. | 27 | $434 |
| Almatica Pharma LLC | 25 | $351 |
| Tris Pharma Inc | 30 | $351 |
| Merck | 15 | $311 |
| Indivior Inc. | 13 | $282 |
| Supernus Pharmaceuticals, Inc. | 11 | $276 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $239 |
| Idorsia Pharmaceuticals US Inc | 11 | $198 |
| Collegium Pharmaceutical, Inc. | 10 | $182 |
| Noven Therapeutics, LLC | 10 | $142 |
| E.r. Squibb & Sons, L.L.C. | 5 | $115 |
| Jazz Pharmaceuticals Inc. | 7 | $114 |
| Sunovion Pharmaceuticals Inc. | 3 | $43 |
| Adlon Therapeutics L.p. | 2 | $41 |
| Braeburn Inc. | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Neos Therapeutics, LP | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Tempus AI, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,006 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 75 | $111,054 |
| RexultiBrexpiprazole | 49 | $71,579 |
| Invega SustennaPaliperidone Palmitate | 15 | $44,496 |
| Abilify MaintenaAripiprazole | 15 | $42,940 |
| TrintellixVortioxetine Hydrobromide | 33 | $25,256 |
| Aripiprazole | 283 | $12,828 |
| Duloxetine Hcl | 210 | $4,864 |
| Lisdexamfetamine Dimesylate | 20 | $4,538 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 118 | $4,052 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 67 | $3,226 |
| Clonazepam | 361 | $2,917 |
| Olanzapine | 114 | $2,587 |
| Buspirone Hcl | 182 | $2,282 |
| Quetiapine Fumarate | 136 | $2,197 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 39 | $2,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,160 | $114,51964 claims |
| AbbVieVraylar | $1,732 | $111,05475 claims |
| Johnson & JohnsonInvega Sustenna | $1,112 | $44,49615 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $239 | $25,25633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Punta Gorda
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.